IMUC (EOM Pharmaceutical Holdings) Accounts Payable: $0.08 Mil (As of Jun. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is EOM Pharmaceutical Holdings Accounts Payable?

EOM Pharmaceutical Holdings IMUC Accounts Payable is $0.08 Mil as of Jun. 2018.

EOM Pharmaceutical Holdings's Accounts Payable for the quarter that ended in Jun. 2018 was $0.08 Mil.

EOM Pharmaceutical Holdings's quarterly Accounts Payable declined from Dec. 2017 ($1.78 Mil) to Mar. 2018 ($1.13 Mil) and declined from Mar. 2018 ($1.13 Mil) to Jun. 2018 ($0.08 Mil).

EOM Pharmaceutical Holdings's annual Accounts Payable increased from Dec. 2015 ($1.16 Mil) to Dec. 2016 ($1.34 Mil) and increased from Dec. 2016 ($1.34 Mil) to Dec. 2017 ($1.78 Mil).

EOM Pharmaceutical Holdings Accounts Payable Related Terms

EOM Pharmaceutical Holdings Accounts Payable Historical Data

* Premium members only.

The historical data trend for EOM Pharmaceutical Holdings's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EOM Pharmaceutical Holdings Accounts Payable Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.86 0.32 1.16 1.34 1.78

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.25 3.77 1.78 1.13 0.08

EOM Pharmaceutical Holdings Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.08 Mil mean?
EOM Pharmaceutical Holdings (IMUC) has a Accounts Payable of $0.08 Mil as of Jun. 2018. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on EOM Pharmaceutical Holdings and its competitors.
Is EOM Pharmaceutical Holdings' Accounts Payable too high?
EOM Pharmaceutical Holdings' current Accounts Payable is $0.08 Mil.
How does EOM Pharmaceutical Holdings' Accounts Payable compare to MNTMD and RTTR?
EOM Pharmaceutical Holdings' Accounts Payable of $0.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on EOM Pharmaceutical Holdings and its competitors. EOM Pharmaceutical Holdings's current Accounts Payable is $0.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EOM Pharmaceutical Holdings stock overvalued right now?
EOM Pharmaceutical Holdings (IMUC) has a current Accounts Payable of $0.08 Mil. The current Accounts Payable is $0.08 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For EOM Pharmaceutical Holdings (IMUC), the current Accounts Payable is $0.08 Mil as of Jun. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EOM Pharmaceutical Holdings Business Description

Address 136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its products have been approved in the U.S., rheumatoid arthritis, and inflammatory conditions of the gastrointestinal tract such as Crohn's Disease and Ulcerative Colitis as well as various retina disorders characterized by a breakdown of the blood-retinal barrier such as diabetic retinopathy, Aged related macular degeneration and retinal vein occlusion among others. Its pipeline includes its compound EOM613, an investigational novel dynamically dual-acting immunomodulator.